Biotech News

Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026

Humacyte (HUMA)HumacyteCompany update

– Humacyte has initiated the CABG clinical study and looks forward to the commencement of screening for potential patients. – “Moving it into a first-in-human study is the step that will tell us whether an off-the-shelf conduit can perform in the coronary position,” says cardiothoracic surgeon

Related news

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

Stock data

Close
0.54 USD
Market cap
308.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States